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The prognosis of renal cell carcinoma (RCC) with venous tumour thrombus (VTT) 
is variable and not always possible to predict. The prognostic impact and inde-
pendence of tumour thrombus-related factors including the recently introduced 
tumour thrombus consistency (TTC) on overall survival remain controversial. The 
aim of this study was to investigate the prognostic role of TTC in patients’ survival. 
We determined the tumour thrombus consistency (solid vs. friable) in a cohort of 
84 patients with RCC and VTT who underwent nephrectomy with thrombectomy, 
and performed a retrospective evaluation of the patients’ data from the prospec-
tively maintained database. A total of 45% of patients had solid thrombus (sTT) 
and 55% had friable thrombus (fTT). The venous tumour thrombus consistency 
was not predictive of overall survival. Further studies, preferably prospective and 
with a larger number of patients, are needed to validate the obtained results, as 
well as to evaluate the usefulness of tumour thrombus consistency in clinical prac-
tice for stratifying the risk of recurrence and planning further follow-up.
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Introduction
Renal cell carcinoma (RCC) is one of the very few 
malignancies with an ability to extend into the venous 
system, and to form a tumour thrombus (TT) involv-
ing the renal vein (RV), inferior vena cava (IVC), or 
even the heart [1, 2]. The estimated VTT prevalence 
ranges between 4% and 36% of all RCC patients, 
and it is most commonly located within the RV [3, 
4]. Although several prognostic clinicopathological 
features including tumour stage, grade, lymph node 
involvement, metastatic status, presence of necrosis 
and sarcomatoid differentiation have been identified 
for RCC patients with VTT, the importance of ve-
nous tumour thrombus consistency in this setting has 
not been well studied to date [5, 6, 7, 8, 9].
In fact, there have been only three studies in total 
that have investigated the significance of TT consis-
tency for patients’ survival, and they produced rather 
conflicting results [10, 11, 12]. To address this vac-
uum, we analysed the impact of tumour thrombus 
consistency on patients’ survival.
Material and methods
This study was carried out in agreement with ap-
plicable laws and regulations, good clinical practice, 
and ethical principles, as described in the Declara-
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tion of Helsinki of 1975, and revised in 2008. We 
retrospectively analysed 639 patients with renal cell 
carcinoma treated with partial, radical or cytoreduc-
tive nephrectomy at a single academic centre (2007-
2015), from a prospectively maintained database. 
Of those, 84 patients had RCC with venous involve-
ment. The records of these patients were reviewed for 
demographics, surgical details, tumour pathology, 
and oncological outcomes.
Preoperative assessment
The cranial extent of the VTT was defined as per 
the Neves and Zincke classification system [13]. The 
level of VTT was assessed in all cases with computed 
tomography (CT) or with magnetic resonance angi-
ography and, in cases with cardiac involvement, ad-
ditionally with transoesophageal echocardiography. 
The presence of synchronous chest metastases was 
evaluated with thoracic CT or chest X-rays, whereas 
bone scans and brain CT were performed when clin-
ically indicated.
Surgery
None of our patients underwent neoadjuvant ther-
apy for the cancer nor was embolised. All patients 
underwent radical or cytoreductive nephrectomy 
with thrombectomy. The surgical approach was de-
termined by the cranial extent of the TT. For level 
0 TT, a laparoscopic approach or flank incision was 
used, while for stages I-IV TT a chevron incision was 
performed. It was extended cephalad to include ster-
notomy when cardiopulmonary bypass was indicated 
or to mobilise the liver for suprahepatic IVC control. 
Cardiopulmonary bypass with moderate hypother-
mic cardiac arrest was performed in 22 cases.
Pathological findings
All microscopic studies were retrospectively re-
viewed by a single uropathologist blinded to the 
patient outcomes. All patients included in the cur-
rent analysis had tumour thrombus tissue available 
for histological examination. The TNM staging was 
Fig. 1. Microscopic view of hematoxylin-eosin stain of a solid (A, B) and friable (C, D) venous tumour thrombus, objective 
magnification 20×
A
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re-classified according to the 2009 Union for Inter-
national Cancer Control/American Joint Committee 
on Cancer TNM staging system based on the histo-
pathological report [14]. Where TNM was not clear, 
the histological slides were reassessed. The morpho-
logical aspect of the TT was classified into solid (sTT) 
or friable (fTT) according to the definition described 
by Bertini et al. [10]. Briefly, in solid TT, tumour 
growth was defined as compact and cohesive, with 
a rounded linear profile and an endothelial lining 
simulating a pseudocapsule (Fig. 1A, 1B). In friable 
TT, tumour cells were defined as intermingled with 
abundant necrosis and fibrin, with a scalloped, irreg-
ular profile and fragmented aspect, sometimes with 
thin papillary features (Fig. 1C, 1D). Finally, TT was 
classified as solid when at least 90% of the samples 
showed solid features.
Follow-up after surgery
The follow-up after surgery was performed at the 
discretion of the urologists and medical oncologists. 
The treatment recurrence differed among practi-
tioners (metastasectomy and/or immunotherapy or 
targeted therapy) and was not considered in the anal-
yses. Data on deaths in people with RCC and VTT 
were obtained from the Death Register of the Polish 
Ministry of Health and Social Welfare and from the 
Register of Births, Marriages and Deaths of the Pol-
ish Registry Office. 
Statistics
Overall survival (OS) was calculated from the date 
of surgery to the date of death from any cause or 
last follow-up. The impact of TT consistency on the 
study variables was analysed using Student’s t test 
and a test for two proportions. The associations be-
tween parameters were examined using Spearman’s 
rank correlation coefficient and multiple logistic re-
gression analyses. Survival curves were estimated 
using the Kaplan-Meier method, and differences 
among survival curves were tested using the log-rank 
test. A p value < 0.05 was considered to indicate sta-
tistical significance. All statistical analyses were per-
formed using the statistical package SPSS for Win-
dows (version 21; SPSS, Chicago, IL, USA).
Results
During the period of the study, a total of 84 pa-
tients with RCC and TT underwent radical or cytore-
ductive nephrectomy and tumour thrombectomy. 
The mean age in the entire group was 64.5 years 
(range: 26-84). There was a preponderance of men 
(59%), right tumours (64%), and clear cell RCC his-
tological subtype (85%). The TT level 0 was in 33 
patients (39%), level I in 10 (11%), level II in 14 
(17%), level III in 9 (10%), and level IV in 17 (20%). 
Overall, 7% of patients had positive lymph nodes 
and 11% had distant metastases.
Of the 84 patients, 38 patients (45%) had solid 
TT, whereas friable TT was identified in 46 patients 
(55%). The distribution of demographic characteris-
tics, as well as clinicopathological features, did not 
differ significantly between these two groups of TTs 
(p < 0.05). The clinicopathological characteristics of 
the entire cohort of patients, as well as of the two 
subcohorts of patients classified as per the TT consis-
tency, are presented in Table I.
The median follow-up was 9 months (range: 1-66 
months, interquartile range 3-20 months). At the 
last follow-up, 49 patients (58%) were alive with-
out evidence of the disease, after a median time of 
10 months from surgery. The median overall sur-
vival was 9 months. The median OS was 10 months 
for patients with solid thrombus, whereas it was 
8 months for patients with friable TT. The compar-
ison of sTT and fTT did not show significant differ-
ences in OS curves during the study period (Fig. 2). 
The p value for 1-, 2-, 3-, and 5-year OS in patients 
with sTT vs. fTT was 0.198, 0.251, 0.714, and 
0.554, respectively.
In the univariate and multivariate analyses only 
Fuhrman grade and presence of distant metastases 
were statistically significant predictors of overall sur-
vival in patients with TT (r = 0.235, p = 0.001, 
and r = 0.191, p = 0.006, respectively). In contrast, 
tumour consistency (sTT vs. fTT), patients’ age, gen-
der, tumour side, pathological tumour stage, tumour 
thrombus level, lymph node involvement, histologi-
cal tumour subtype, tumour necrosis, invasion of the 
venous wall by a thrombus, and tumour fat invasion 
were not found to impact survival in the current 
study.
Discussion
Despite many efforts in elucidating the impact of 
venous tumour thrombus on survival of patients with 
RCC, controversies surrounding this issue remain. 
While several clinicopathological features including 
cephalad extension of TT have been proposed as in-
dependent prognostic factors for patients’ survival by 
some investigators, their role in that setting has not 
been confirmed by others and is still under debate 
[5, 6, 7, 8, 9].
Recently, three studies have investigated the ef-
fect of the venous tumour thrombus consistency 
on the postoperative survival in patients with RCC 
and TT [10, 11, 12]. Consistent with these studies, 
we retrospectively assessed the prognostic signifi-
cance of thrombus consistency in a cohort of 84 pa-
tients with TT.
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Table I. Patient characteristics and descriptive statistics
all paTienTs sOlid TT (n = 38) Friable TT (n = 46) p
Mean age, years, ±SD (range) 64.5 ±11.0 (26-84) 63.8 ±11.5 (26-84) 65.0 ±10.7 (26-84) 0.618
Sex, n (%)
Male 50 (59.5%) 22 (57.9%) 28 (60.9%) 0.782
Female 34 (40.5%) 16 (42.1%) 18 (39.1%) 0.782
Side, n (%)
Right 54 (64.3%) 28 (73.7%) 26 (56.5%) 0.102
Left 30 (34.7%) 10 (23.3%) 20 (43.5%) 0.102
TT level, n (%)
0 33 (39.3%) 18 (47.4%) 15 (32.6%) 0.168
1 10 (11.9%) 5 (13.2%) 5 (10.9%) 0.747
2 14 (17.9%) 6 (15.8%) 9 (19.6%) 0.653
3 9 (10.7%) 4 (10.5%) 5 (10.9%) 0.960
4 17 (20.2%) 5 (13.2%) 12 (26.1%) 0.142
Histological subtype, n (%)
Clear cell RCC 71 (85.5%) 34 (91.9%) 37 (80.4%) 0.254
Others 12 (14.5%) 3 (8.1%) 9 (19.6%) 0.128
Sarcomatoid features, n (%)
3 (3.6%) 2 (5.3%) 1 (2.2%) 0.448
Fuhrman grade, n (%)
1+2 29 (34.5%) 19 (22.6%) 10 (11.9%) 0.07
3 37 (44.0%) 13 (34.2%) 24 (52.2%) 0.099
4 18 (21.4%) 6 (15.8%) 12 (26.1%) 0.252
Perinephric fat invasion, n (%)
Yes 52 (61.9%) 21 (55.3%) 31 (67.4%) 0.255
No 32 (38.1%) 17 (44.7%) 15 (32.6%) 0.255
Tumour necrosis, n (%)
Yes 31 (36.9%) 10 (26.3%) 21 (45.7%) 0.068
No 53 (63.1%) 28 (73.7%) 25 (54.3%) 0.068
Venous wall cancer invasion, n (%)
Yes (%) 15 (39.5%) 17 (37.0%) 0.813
No (%) 23 (60.5%) 29 (63.0%) 0.813
Urinary collecting system invasion, n (%)
Yes 13 (15.5%) 5 (13.2%) 8 (17.4%) 0.593
No 71 (84.5%) 33 (86.8%) 38 (82.8%) 0.593
pT stage, n (%)
pT3a 43 (51.8%) 22 (59.5%) 21 (45.7%) 0.264
pT3b 20 (24.1%) 9 (24.3%) 11 (23.9%) 0.980
pT3c 14 (16.9%) 5 (13.5%) 9 (19.6%) 0.434
pT4 6 (7.2%) 1 (2.7%) 5 (10.9%) 0.144
Nodal status, n (%)
pN0/cNo 76 (90.5%) 35 (92.1%) 41 (89.1%) 0.644
pN+ 8 (9.5%) 3 (7.9%) 5 (10.9%) 0.644
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In the present study TTC was not a predictor of 
OS. Our findings are in concordance with the previ-
ous report by Antonelli et al., who found that throm-
bus consistency was not a statistically significant and 
clinically relevant prognostic factor for either OS or 
cancer-specific survival when used together with oth-
er pathological and clinical predictors [12].
However, our findings are in disagreement with 
the two earlier studies that suggested friable TT to 
be associated with worse prognosis [10, 11]. The 
observed differences regarding the predictive value 
of TTC among our and the aforementioned studies 
may be due to two main reasons. Firstly, there were 
marked differences in the number of patients with 
fTT vs. sTT among the studies. In our study, the 
fTT to sTT ratio was 1.22 and was close to the one 
reported by Antonelli et al. (0.85) [12], whereas in 
the study by Bertini et al. it was 0.15 [10], and in 
the analysis by Weiss et al. it was 0.63 [11]. The low 
proportion of fTT combined with the limited sample 
size could have had an effect on the results reported 
by the group of researchers led by Bertini and Weiss. 
Secondly, in the previous studies, the two subcohorts 
of patients with RCC and TT, i.e. patients with fTT 
and with sTT, had statistically different demographic 
as well as clinicopathological characteristics, includ-
ing several potentially prognostic predictors (tumour 
grade, pathological stage, nodal status, distant me-
tastases, tumour necrosis, TT level, and histological 
subtype), with adverse features dominating in the 
patients with fTT. The heterogeneity of the analysed 
groups of patients is a likely source of a selection bias 
and might have had an effect on the patients’ sur-
vival.
Strengths and limitations of the study
Our study was a retrospective analysis of a limit-
ed number of patients and as such is subject to the 
bias and limitations inherent to this type of study. 
However, the data used in the analyses were obtained 
from a prospectively maintained database, which re-
duced the risk of errors and/or omissions. The two 
groups of patients were relatively homogeneous, 
and there were no differences in the baseline clinico-
pathological characteristics of the two groups of pa-
tients. The relatively short-term follow-up restricted 
to some extent our results. Moreover, we used only 
overall survival as the endpoint of our study, as the 
cause of death could not have been determined reli-
ably in all patients, and hence cancer-specific survival 
would have been likely affected. However, it should 
be noted that OS is the gold standard for cancer clin-
ical research and is considered the most reliable and 
preferred cancer endpoint [15]. 
In conclusion, this study showed that TTC does 
not predict survival in patients with renal cell carci-
noma and venous tumour thrombus. Further studies, 
preferably prospective and with a larger number of 
patients, are needed to validate the obtained results, 
as well as to evaluate the usefulness of TTC in clini-
cal practice for stratifying the risk of recurrence and 
planning follow-up.
The authors declare no conflicts of interest.
Fig. 2. Overall survival curves for patients with renal cell 
carcinoma and solid tumour thrombus or friable tumour 
thrombus extending into the venous system
TT – tumour thrombus; n – number of patients; SD – standard deviation; pT stage – pathological tumour stage; c – clinical; p – pathological; N – lymph nodes;  
M – distant metastases; * – statistically significant
Distant metastases, n (%)
cM0 74 (88.1%) 34 (89.5%) 40 (87.0%) 0.723
cM1 10 (11.9%) 4 (10.5%) 6 (13.0%) 0.723
Table I. Cont.
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